The Level of Autoantibodies Targeting Eukaryote Translation Elongation Factor 1 α1 and Ubiquitin-Conjugating Enzyme 2L3 in Nondiabetic Young Adults
Diabetes & Metabolism Journal
;
: 154-160, 2016.
Article
in English
| WPRIM
| ID: wpr-15196
ABSTRACT
BACKGROUND:
The prevalence of novel type 1 diabetes mellitus (T1DM) antibodies targeting eukaryote translation elongation factor 1 alpha 1 autoantibody (EEF1A1-AAb) and ubiquitin-conjugating enzyme 2L3 autoantibody (UBE2L3-AAb) has been shown to be negatively correlated with age in T1DM subjects. Therefore, we aimed to investigate whether age affects the levels of these two antibodies in nondiabetic subjects.METHODS:
EEF1A1-AAb and UBE2L3-AAb levels in nondiabetic control subjects (n=150) and T1DM subjects (n=101) in various ranges of age (18 to 69 years) were measured using an enzyme-linked immunosorbent assay. The cutoff point for the presence of each autoantibody was determined based on control subjects using the formula [mean absorbance+3×standard deviation].RESULTS:
In nondiabetic subjects, there were no significant correlations between age and EEF1A1-AAb and UBE2L3-AAb levels. However, there was wide variation in EEF1A1-AAb and UBE2L3-AAb levels among control subjects <40 years old; the prevalence of both EEF1A1-AAb and UBE2L3-AAb in these subjects was 4.4%. When using cutoff points determined from the control subjects <40 years old, the prevalence of both autoantibodies in T1DM subjects was decreased (EEFA1-AAb, 15.8% to 8.9%; UBE2L3-AAb, 10.9% to 7.9%) when compared to the prevalence using the cutoff derived from the totals for control subjects.CONCLUSION:
There was no association between age and EEF1A1-AAb or UBE2L3-AAb levels in nondiabetic subjects. However, the wide variation in EEF1A1-AAb and UBE2L3-AAb levels apparent among the control subjects <40 years old should be taken into consideration when determining the cutoff reference range for the diagnosis of T1DM.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Reference Values
/
Autoantibodies
/
Enzyme-Linked Immunosorbent Assay
/
Peptide Elongation Factors
/
Prevalence
/
Peptide Elongation Factor 1
/
Diabetes Mellitus, Type 1
/
Diagnosis
/
Eukaryota
/
Antibodies
Type of study:
Diagnostic study
/
Prevalence study
Limits:
Humans
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS